IA

PSI Awarded $91.7 Million Recompete to Provide C2MS III Support to U.S. Air Force Special Operations Command

Retrieved on: 
Wednesday, August 10, 2022 - 2:18pm

This single-award task order contract has a value of over $91.7 million.

Key Points: 
  • This single-award task order contract has a value of over $91.7 million.
  • Under the contract, PSI will continue its support of the current mission and priorities of AFSOC, including Content Management for Department of Defense (DoD) Field Units; Cloud Migration and Cloud Support for Air Force Special Operations Forces (AFSOF) and other Federal Agencies; and Research, Development, Test and Evaluation support for Strategic Capabilities Office Initiatives.
  • PSI will bring a mixture of mission and platform knowledge, technical innovation, and DevSecOps capabilities to enhance AFSOCs critical mission to organize, train, educate and equip forces to conduct special operations missions worldwide.
  • Under this important recompete win, we commit to continuing our strong partnership with AFSOC by delivering innovative technology and actionable intelligence that will set the bar for advancing their global mission.

ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, August 6, 2022 - 2:00am

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) on behalf of Atara stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) on behalf of Atara stockholders.
  • Our investigation concerns whether Atara has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On November 4, 2021, Atara issued a press release touting its T cell immunotherapy product candidate, ATA188.
  • In this release, the Company claimed that there was "positive momentum around the ATA188 program" and "increasing awareness of and excitement .

Bragar Eagel & Squire, P.C. Is Investigating TuSimple, Atara, Mercury, and the WWE and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, August 6, 2022 - 2:00am

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • The article alleges that one of the Companys autonomously driven trucks left its lane of travel without warning before striking a cement barricade.
  • The article also reveals that the Federal Motor Carrier Safety Administration has launched a safety compliance investigation.
  • For more information on the WWE investigation go to: https://bespc.com/cases/WWE
    About Bragar Eagel & Squire, P.C.

ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, August 5, 2022 - 2:00am

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) on behalf of Atara stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) on behalf of Atara stockholders.
  • Our investigation concerns whether Atara has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On November 4, 2021, Atara issued a press release touting its T cell immunotherapy product candidate, ATA188.
  • In this release, the Company claimed that there was "positive momentum around the ATA188 program" and "increasing awareness of and excitement .

Upcoming HR Technology Conference & Exposition® to Feature Record Number of Sessions, Industry’s Largest Marketplace

Retrieved on: 
Wednesday, August 3, 2022 - 12:00pm

PALM BEACH GARDENS, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- The HR Technology Conference & Exposition returns next month with a record number of sessions and the industrys largest marketplace, offering attendees a first-hand look at the changing face of human resources.

Key Points: 
  • PALM BEACH GARDENS, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- The HR Technology Conference & Exposition returns next month with a record number of sessions and the industrys largest marketplace, offering attendees a first-hand look at the changing face of human resources.
  • With more than 120 sessions and over 400 exhibitors, HR Tech remains an unparalleled immersive experience for todays workforce leaders.
  • This years Expo will feature HR Tech Talks, Case Studies and Demo Theaters, plus a Startup Pavilion and the annual Pitchfest competition.
  • The Human Resource Executive HR Technology Conference & Exposition has helped tens of thousands of HR professionals make smarter and better-informed decisions regarding their organizations HR technology investments with a world-class educational program.

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Atara Biotherapeutics, Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Thursday, July 28, 2022 - 10:18pm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • Atara issued a press release on July 12, 2022, updating the market on its preliminary analysis phase 2 EMBOLD study for product candidate ATA188.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

ATRA INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Atara Biotherapeutics, Inc.

Retrieved on: 
Wednesday, July 27, 2022 - 3:49pm

New York, New York--(Newsfile Corp. - July 27, 2022) - Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) concerning possible violations of federal securities laws.

Key Points: 
  • New York, New York--(Newsfile Corp. - July 27, 2022) - Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) concerning possible violations of federal securities laws.
  • On November 4, 2021, Atara issued a press release touting its T cell immunotherapy product candidate, ATA188.
  • In this release, the Company claimed that there was "positive momentum around the ATA188 program" and "increasing awareness of and excitement .
  • Then, on February 28, 2022, Atara issued a press release attached to their Form 8-K, providing an update on ATA188.

Equinor to commence third tranche of the 2022 share buy-back programme

Retrieved on: 
Wednesday, July 27, 2022 - 5:48am

Equinor (OSE: EQNR, NYSE: EQNR) will commence on 28 July 2022 the third tranche of around USD 1.833 billion of the 2022 share buy-back programme, as announced in relation with the second quarter results on 27 July 2022.

Key Points: 
  • Equinor (OSE: EQNR, NYSE: EQNR) will commence on 28 July 2022 the third tranche of around USD 1.833 billion of the 2022 share buy-back programme, as announced in relation with the second quarter results on 27 July 2022.
  • The third tranche will commence on 28 July and will end no later than 26 October 2022.
  • The purpose of the share buy-back programme is to reduce the issued share capital of the company.
  • Further information about the share buy-back programme and the second tranche:
    The third tranche of the share buy-back programme for 2022 is based on an authorisation granted to the Board of Directors at the annual general meeting 11 May 2022.

Insurance Agents Expect Online Commercial Insurance Shoppers to Nearly Double in Next Three Years, Says New Survey

Retrieved on: 
Wednesday, July 20, 2022 - 2:00pm

NEW YORK, July 20, 2022 /PRNewswire/ -- The majority of independent insurance agents (53%) are expecting a significant increase in online commercial insurance buyers over the next three years, according to a survey from Semsee, the go-to platform for selling commercial insurance, and TrustedChoice.com, the nation's largest digital marketing platform for independent agents and brokers. The new study of independent agents focused on the ways agents find and win new commercial insurance business.

Key Points: 
  • The new study of independent agents focused on the ways agents find and win new commercial insurance business.
  • Overall, 42% of agents surveyed say they are seeing an increase in commercial opportunities since the start of the pandemic in early 2020.
  • Three-quarters of agents told us they're using online portals to get this information, meaning they're entering data multiple times," said Philip Charles-Pierre, CEO, Semsee.
  • The TrustedChoice.com consumer website has attracted over 37 million insurance shoppers and offers online insurance consumers a retail-like buying experience, connecting the right risk to the right agent at the right buying moment.

Ascend Partners with Independent Insurance Agents of North Carolina As The Preferred Payments & Financing Platform For Their Independent Agency Channel

Retrieved on: 
Friday, July 15, 2022 - 2:00pm

NEW YORK, July 15, 2022 /PRNewswire/ -- Today, Ascend , a modern insurance payments platform, announced a partnership with Independent Insurance Agents of North Carolina (IIANC), which has named Ascend as its preferredpremium payments company for its members.

Key Points: 
  • NEW YORK, July 15, 2022 /PRNewswire/ -- Today, Ascend , a modern insurance payments platform, announced a partnership with Independent Insurance Agents of North Carolina (IIANC), which has named Ascend as its preferredpremium payments company for its members.
  • Ascend is the first modern insurance payments platform that provides automated all-in-one financing, collections, and payables.
  • The two have come together to provide value specific to payments for IIANC's independent agency channel.
  • The Independent Insurance Agents of North Carolina ("IIANC") is a statewide trade association representing nearly 900 independent insurance agencies in North Carolina, with more than 7,000 employees, who work to protect the insurance and financial needs of the state's citizens.